Menu
← Oncology Approval Tracker
FDA DECISION ·
Lyrfigtu
lirafugratinib · Elevar Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement.
LAMPGEN ANALYSIS
Why it matters
This gives a molecularly selected biliary tract cancer population another FGFR-targeted option. REFOCUS enrolled patients without prior FGFR inhibitor treatment, which is important when discussing sequencing.
What research teams should watch
Make the FGFR2 fusion or rearrangement result retrievable across outside pathology, molecular labs and the study record. Keep prior FGFR inhibitor exposure separate from prior chemotherapy.
PRIMARY RECORDS